tbuckley/cabot-search huggingface dataset:
AB1347 Elevated nesfatin-1 levels in patients with rheumatoid arthritis
Authors: T.Z. Kvlividze, B.V. Zavodovsky, Y.R. Akhverdyan, L.E. Sivordova, Y.V. Polyakova, D.P. Lavrova, A.T. Yakovlev
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Recent studies indicate that adipokines affect tissues and cells involved in rheumatoid arthritis (RA), including synovium, cartilage, bone, and immune cells.<sup>1, 2, 3</sup> Nesfatin-1, a member of the adipokine family, was identified in 2006 as a potent anorexigenic peptide involved in the regulation of homeostatic feeding. Nesfatin-1 concentrations in serum and synovial fluid were closely correlated with disease occurrence and severity of knee osteoarthritis.<sup>4</sup> We did not found any data about Nesfatin-1 levels in sera of rheumatoid arthritis (RA) patients. <h3>Objectives</h3> To investigate the serum nesfatin-1 level in RA patients. <h3>Methods</h3> At baseline we measured Nesfatin-1 level in sera of 110 RA patients (mean age 54,07±11,32; hereinafter M±Std.dev.) and 60 healthy controls (52,09±14,12). The diagnosis of RA was set according to the ACR/.<sup>EULAR Classification Criteria for RA (2010)</sup> Serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured to assess inflammation severity. Nesfatin-1 in serum was determined by enzyme-linked immunosorbent assay (RaiBiotech, cat№ EIA-NESF). <h3>Results</h3> We revealed that nesfatin-1 levels in RA patients was equal 50,49±34,05 ng/ml and was higher than of healthy controls – 31,61±3,17 ng/ml. We divided 120 RA patients into 2 subgroups – 1st (n=44) with normal nesfatin-1 concentration in sera, and 2nd (n=66) – with increased nesfatin-1 level. We noted that 2nd group's patients had higher DAS28 activity index, functional joints disability, higher levels CRP and ESR. <h3>Conclusions</h3> The present study shows that RA patients have increased serum Nesfatin-1 levels which strongly correlated with systemic inflammation and functional impairment in RA. These data sustained the pathogenic role of Nesfatin-1 in RA progression. <h3>References</h3> [1] Sivordova U, Zavodovsky B, Polyakova U, et all. Adiponectin as a useful marker for diagnosis of osteoporosis in rheumatoid arthritis patients. Osteoporosis Int. 2016;27(S.1):135 [2] Seewordova L, Polyakova U, Zavodovsky B, et al. Adiponectin determination in rheumatoid arthritis patients complicated by osteoporosis. EULAR2016;75(S.2):970–971. [3] Polyakova Y, Sivordova L, Akhverdyan Y, Kravtcov V, Zavodovsky B. New biomarker for diagnosis of osteoporosis in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2017 -76, 2- 699. [4] Zhang Y, Shui X, Lian X, Wang G. Serum and synovial fluid nesfatin-1 concentration is associated with radiographic severity of knee osteoarthritis. Med Sci Monit. 2015;21:1078–1082. <h3>Disclosure of Interest</h3> None declared
Assessing the Performance of Aging Surgeons
Authors: Mark R. Katlic, JoAnn Coleman, Marcia M. Russell
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses
Authors: S. J. Santegoets, C. L. Duurland, E. S. Jordanova, J. J. van Ham, I. Ehsan, S. L. van Egmond, M. J. P. Welters, S. H. van der Burg
Journal: Journal for ImmunoTherapy of Cancer (2019)

Regulatory T cells (Tregs) may comprise different subsets allowing them to efficiently suppress different types of effector T cells. In this study, we show that high numbers of both conventional and Tbet co-expressing Foxp3<sup>hi</sup> Tregs accumulate in human papilloma virus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC). The infiltration of Tbet+ Foxp3+ Tregs was strongly correlated with a concomitant tumor-specific and conventional type 1-oriented intratumoral T cell infiltrate. Both conventional CD4+CD25+CD127–Foxp3<sup>hi</sup> Tregs and their Tbet<sup>hi</sup> counterparts exhibited an activated phenotype, co-expressed high levels of CTLA4 and Helios and exhibited a maximally demethylated Foxp3 gene locus TSDR, indicating their full capacity to impede a type 1 effector T cell response. Interestingly, while the prognostic value of conventional Tregs was neutral, a high intratumoral frequency of Tbet+ Tregs was associated with prolonged disease-specific survival, most likely because their presence reflected high numbers of effector T cells. The presence of these Tbet+ Tregs may in part explain why a dense type 1-oriented immune infiltrate in OPSCC is not enough to fully control tumor growth.
THU0171 Identification of methotrexate-induced pulmonary toxicity cases in a fully searchable routine clinical database
Authors: N. Hasler, S. Irani, P. Schütz, P. Hasler
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Methotrexate (MTX) remains the favoured disease-modifying anti-rheumatic drug for the treatment of rheumatoid arthritis (RA) and is frequently used in other inflammatory conditions. However, side effects are frequent and toxicity is of concern, especially since MTX-induced pulmonary side effects, including pneumonitis, are potentially fatal. Estimates of MTX-induced pneumonitis in the literature range from 0.3% to 7.5% of exposed cases (Barrera et al., 1994 Kremer et al., 1997). <h3>Objectives</h3> We aimed to identify and characterise MTX-induced lung injury in patients exposed to low-dose MTX at the Rheumatology Division of the Kantonsspital Aarau, Switzerland. <h3>Methods</h3> The revised diagnostic criteria for adverse pulmonary events due to MTX treatment as defined by Kremer et al 1997 were used to categorise MTX-induced lung injury. The electronic patient files of the Rheumatology Division are stored in a NoSQL-database (MongoDB)<b>,</b> which is fully addressable by the Solr search platform (Apache Lucene). The entire database was searched for terms associated with methotrexate exposure and potential pulmonary side effects. <h3>Results</h3> Of 9'550 cases, 11 fulfilled the criteria for definite MTX-induced pulmonary injury, while three additional patients could be classified as suffering from probable MTX-induced pulmonary side effects. To determine the number of exposed cases, the case files were queried for the mention of MTX and related terms. 1'947 case files contained a reference to MTX. In a random sample of 395 of these cases, an exposure to MTX was verified in 328 (83%). Assuming a calculated exposure of 1'639 cases, MTX-induced lung injury was present in 0.85%. <h3>Conclusions</h3> In a comprehensive survey of patients exposed to MTX in a fully searchable routine clinical database, MTX-induced pulmonary injury occurred in a low frequency. <h3>References</h3> [1] Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, &amp; van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis1994;53(7):434–439. [2] Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum1997;40(10):1829–1837. <h3>Acknowledgements</h3> Urs Rutschi, Stefan Hubeli, Alex Souza, Iterata AG, Gränichen, Switzerland, for assistance with data extraction strategies. <h3>Disclosure of Interest</h3> None declared
AB1096 Observational safety study of golimumab in treatment of polyarticular juvenile idiopathic arthritis using the german biologics jia registry
Authors: G. Horneff, A. Klein
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Golimumab (GLM) received European marketing authorisation for treatment of polyarticular JIA (pJIA). The long-term safety of GLM in clinical preactice has not been characterised. <h3>Objectives</h3> The aim of the present project is to conduct a post-authorisation safety study to monitor long-term safety of subcutaneous GLM in the treatment of pJIA in routine clinical practice setting. <h3>Methods</h3> Monitoring of GLM in 200 pts with polyarticular JIA (cohort 1) in clinical practice will be performed by the German BiKeR Registry compared to a concurrent cohort 2 with 400 pts newly treated with alternative (approved) TNF-inhibitor, a concurrent cohort 3 with 500 pts newly starting methotrexate, a historic cohort 4 of patients treated with TNF-inhibitors and a historic cohort 5 never exposed to biologics but treated with methotrexate. Efficacy will be assessed by single disease activity markers and JADAS10, safety will be assessed by adverse event reporting and monitoring with a special interest on serious infections including opportunistic infections and TB, malignancies, autoimmune processes and exposure during pregnancy. <h3>Results</h3> Recruiting of three new cohorts 1–3 started in July 2017. Historic control cohorts 4 and 5 were obtained from the BIKER data base. Cohort 4 was recruited from 2006 to 2016, cohort 5 from 2005 to 2011. Baseline patients’ characteristics are outlined in table 1. So far, patients of the GLM cohort 1 were older, had a much longer disease duration and received pre-treatment with other biologics more often. All patients in this cohort received combination with methotrexate. Since so far GLM is approved for children with body weight of at least 40 kg and in combination with methotrexate, differences were expected. Baseline disease activity indicators are within the range of alternative TNF inhibitors and the historic cohort 4 while patients of the concurrent methotrexate cohort receiving their first treatment approach had the highest baseline disease activity. <h3>Conclusions</h3> The BiKeR registry has been collecting data from JIA patients treated with approved biologics in routine clinical practice since 2001. To provide context for interpreting long-term safety and effectiveness of data for GLM, analysis will also include data from contemporary pJIA patients treated with alternative TNF inhibitors and methotrexate. <h3>Acknowledgements</h3> This project of the BIKER registry is supported by an unrestricted grant from MSD, Germany <h3>Disclosure of Interest</h3> None declared
Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia
Authors: Bhumika J. Patel, Shimoli Vipul Barot, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hassan Awada, Metis Hasipek, Swapna Thota, Tomas Radivoyevitch, Anjali S. Advani, Matt Kalaycio, Mikkael A. Sekeres, Hetty E. Carraway, Jaroslaw P. Maciejewski
Journal: Blood (2018)
Epidemiology of time-loss injuries in international fencing: a prospective, 5-year analysis of Fédération Internationale d’Escrime competitions
Authors: Peter A Harmer
Journal: British Journal of Sports Medicine (2019)

The study aimed to determine the risk of time-loss injuries in international fencing and to characterise their type, location, severity and mechanism. Variations in risk associated with sex and discipline categories are also examined.Data on participation and withdrawal due to injury from 809 competitions comprising the major events of the 2010-2014 seasons (inclusive) for the Fédération Internationale d'Escrime were compiled from official results. Athletes who withdrew due to injury sustained in each competition were contacted individually to obtain follow-up information including time lost from fencing participation (practice/competition) and sequelae.A total of 176 injuries were recorded from 637 776 athlete exposures (AEs) in 85 686 participants (men=47 869; women=37 817) over the study period, for an overall incidence of 0.28/1000 AEs (95% CI 0.24 to 0.32). Men had significantly greater risk than women (RR=1.42, 95% CI 1.05 to 1.94); épée had a significantly lower risk than foil or sabre (RR=0.52, 95% CI 0.35 to 0.76; RR=0.47, 95% CI 0.32 to 0.69, respectively). The majority of injuries were sprains (40.8%) and strains (20.1%), which occurred in the lower extremities (72.4%); ankle sprains were the most common specific injury (25.3%). Intrinsic effort of the fencer (non-contact injury) was the most common mechanism related to a time-loss injury (47.1% of cases). The overall median time loss was 4 weeks; 32.1% of the injuries involved 2 weeks or less away from fencing participation.The data indicate that the risk of time-loss injury in international fencing is very low and primarily involves sprains and strains in the lower extremity.
An Unexpectedly High Frequency of Sptb Gene Mutation (SPTB exon 29: c.6055T&gt;C (p.Ser2019Pro; Spectrin Thai)) with a Single Origin in Thailand Suggesting a New Model of Red Blood Cell Trait Against Malarial Pressure
Authors: Supachai Ekwattanakit, Jiraporn Korchuenjit, Thidarat Suksangpleng, Suchada Riolueang, Tana Taechalertpaisarn, Parichat Prommana, Pakatip Silapamongkolkul, Komgrid Charngkaew, Sittiruk Roytrakul, Chairat Uthaipibull, Vip Viprakasit
Journal: Blood (2018)
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience
Authors: M Hasib Sidiqi, Mohammed A Aljama, Angela Dispenzieri, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I Gonsalves, Prashant Kapoor, Taxiarchis Kourelis, William J. Hogan, S. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz
Journal: Blood (2018)
SAT0652 Study of nail unit with ultrasonography in several rheumatological conditions: a cross sectional study of distal interphalangeal joint and nail
Authors: G. Adami, E. Vantaggiato, C. Benini, A. Fassio, A. Giollo, G. Orsolini, L. Idolazzi, D. Gatti
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The ultrasonography (US) is a feasible technique when you refer to the peripheral small joints and also to the nail.<sup>1</sup> DIP joints are not only affected by inflammatory disease and a more frequent condition is osteoarthritis (OA). The bone and synovial changes due to this condition are very similar to the ones of PSA especially regarding osteoproliferative lesions. <h3>Objectives</h3> The aim of our study was exploring through imaging the changes of nail and enthesis of extensor tendon of the finger in inflammatory and degenerative conditions in order to find structural differences of nail and DIP. <h3>Methods</h3> This is an observational study on PSO, PSA, RA or OA patients. A control group of 50 healthy volunteers was used for comparison. Diagnosis was based on clinical or scientific criteria, such as CASPAR or EULAR/ACR were applicable. The study sample included 203 individual. The ultrasonographers were blind to clinical data and diagnosis of the patient. The ultrasound examination was done with a GE Logiq S8. The structural alterations of the plate were evaluated using a semiquantitative score for the magnitude of the alteration. The score provides values from 0 (no alteration) to 3 (severly altered). A semiquantitative approach was also used for evaluation of the power Doppler signal. <h3>Results</h3> The study sample was composed by 51 patients affected by PsA, 31 affected by PSO group, 37 subjects with RA, 34 with OA and 50 HC. The analysis of nail bed PDUS revealed an unusual trend for patients affected by OA who showed a prevalence of lesions of every grade but a lower rate of normal cases. The evaluation of the PDUS of the enthesis revealed that patients affected by PsA have an increased rate of PDUS signal at the enthesis of the extensor tendon. Considering nail plate HC showed a strong difference (p value&lt;0.001) vs all groups except for patients affected by RA. Regarding nail bed thickness HC showed difference only if compared with PSA or OA group. P values are reported in table 1. <h3>Conclusions</h3> The data support the concept that nail enthesis unit is in some way involved in different pathological conditions. No exclusive feature belongs only to one or another disease, but the data provided suggested that peculiar lesions might be found only in certain disease and in certain structures, like the entheses. The US of the nail should be considered as one of the possible and promising approach in the study of these structures. <h3>Reference</h3> [1] Arbault A, Devilliers H, Laroche D, et al. Reliability, validity and feasibility of nail ultrasonography in psoriatic arthritis. Jt Bone Spine Rev Rhum2016;83:539–44. doi:10.1016/j.jbspin.2015.11.004 <h3>Disclosure of Interest</h3> None declared
AB0033 B regulatory cells positively correlate with antibodies against ss-a ro52 in systemic sclerosis
Authors: A. Mavropoulos, A. Gkoutzourelas, T. Simopoulou, C. Liaskos, D.P. Bogdanos, L.I. Sakkas
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> We and Japanese Investigators have shown that IL-10-producing regulatory B cells (B10 cells) are decreased in systemic sclerosis (SSc).<sup>1 2</sup> Contrary to the Japanese, we did not find a negative correlation between B10 cells and SSc-specific autoantibodies (autoabs) against centromere, Scl-70 or RNA polymerase III.<sup>3</sup> Since we found anti-Ro52 SS-A antibodies in approx. 30% of patients with SSc,<sup>4</sup> this being the 3rd most frequent autoantibody in this disease, we considered what is the relation of B10 cells with anti-Ro52 antibodies. <h3>Objectives</h3> We examined the number and function of Bregs in SSc in relation to anti-Ro52 autoabs. <h3>Methods</h3> Serum samples and PBMCs were collected from 40 SSc patients (15 anti-Scl-70, 20 anti-CEN and 5 anti-RNA pol III) and were further divided according to anti-Ro52-positivity into 22 anti-Ro52(+) and 18 anti-Ro52 (-). All serum samples were tested for the presence of disease-specific autoantibodies against Scl-70, CENP, RNA-pol, and against Ro52 using a line assay (Euroimmun Germany). The function of Bregs was determined by the ability to express IL-10 following activation with <sup>ODN 2006</sup> (TLR-9). Percentages of transitional (CD19 +CD24highCD38high) and memory (CD19 +CD27+CD24 high) Bregs were assessed by flow cytometry using fluorochrome conjugated antibodies (BD Biosciences). <h3>Results</h3> IL-10(+) Bregs (B10) were significantly elevated in SSc patients (6.7%±2.6% n=15) with high-titre antibodies against Ro52 (mean anti-Ro52 arbitrary units AU &gt;100; positivity cut-off AU &gt;20) compared to patients (4.2%±1.9%, n=22) totally negative for Ro52 (mean AU &lt;10) (p=0.03). Transitional Bregs were also significantly increased in all SSc patients tested positive for anti-Ro52 autoantibodies (7.5%±1.9%) compared to SSc patients negative for anti-Ro52 autoantibodies (3.7±0.8, p=0.02). Furthermore, transitional Bregs positively correlated with anti-Ro52 antibody levels (r<sup>2</sup>=0.39 p=0.01). In contrast, memory Bregs were not significantly different between anti-Ro52-positive (14.1%±2.7%) and -negative SSc patients (11.8%±2.2%) (p&gt;0.05). <h3>Conclusions</h3> IL10-producing Bregs are higher in SSc patients with high anti-Ro52 antibodies and transitional Bregs correlated with antiRo52 antibodies in patients with SSc suggesting that this autoantibody could be a potential marker of Breg efficiency. <h3>References</h3> [1] Mavropoulos A, et al. Arthritis Rheumatol2016;68(2):494–504. [2] Matsushita T, et al. Rheumatology2016;55(2):263–67. [3] Mavropoulos A, et al. Clin Immunol2017;184:26–32. [4] Liaskos C, et al. Autoimmunity2017;50(7):414–421. <h3>Disclosure of Interest</h3> None declared
Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness
Authors: Joseph F. Hayes, Andreas Lundin, Susanne Wicks, Glyn Lewis, Ian C. K. Wong, David P. J. Osborn, Christina Dalman
Journal: JAMA Psychiatry (2019)

Drug repurposing is potentially cost-effective, low risk, and necessary in psychiatric drug development. The availability of large, routine data sets provides the opportunity to evaluate the potential for currently used medication to benefit people with serious mental illness (SMI).To determine whether hydroxylmethyl glutaryl coenzyme A reductase inhibitors (HMG-CoA RIs), L-type calcium channel (LTCC) antagonists, and biguanides are associated with reduced psychiatric hospitalization and self-harm in individuals with SMI.These within-individual cohort studies of patients with SMI compared rates of psychiatric hospitalization and self-harm during periods of exposure and nonexposure to the study drugs, with adjusting for a number of time-varying covariates. Participants included 142 691 individuals from the entire population of Sweden with a diagnosis of bipolar disorder (BPD), schizophrenia, or nonaffective psychosis (NAP) who were 15 years or older and who were treated with psychiatric medication from October 1, 2005, through December 31, 2016. Data were analyzed from April 1 through August 31, 2018.Treatment with HMG-CoA RIs, LTCC antagonists, or biguanides.Psychiatric hospitalizations and self-harm admissions.Among the 142 691 eligible participants, the HMG-CoA RI exposure periods were associated with reduced rates of psychiatric hospitalization in BPD (adjusted hazard ratio [aHR], 0.86; 95% CI, 0.83-0.89; P < .001), schizophrenia (aHR, 0.75; 95% CI, 0.71-0.79; P < .001), and NAP (aHR, 0.80; 95% CI, 0.75-0.85; P < .001) and reduced self-harm rates in BPD (aHR, 0.76; 95% CI, 0.66-0.86; P < .001) and schizophrenia (aHR, 0.58; 95% CI, 0.45-0.74; P < .001). Exposure to LTCC antagonists was associated with reduced rates of psychiatric hospitalization and self-harm in subgroups with BPD (aHRs, 0.92 [95% CI, 0.88-0.96; P < .001] and 0.81 [95% CI, 0.68-0.95; P = .01], respectively), schizophrenia (aHRs, 0.80 [95% CI, 0.74-0.85; P < .001] and 0.30 [95% CI, 0.18-0.48; P < .001], respectively), and NAP (aHRs, 0.89 [95% CI, 0.83-0.96; P = .002] and 0.56 [95% CI, 0.42-0.74; P < .001], respectively). During biguanide exposure, psychiatric hospitalization rates were reduced in subgroups with BPD (aHR, 0.80; 95% CI, 0.77-0.84; P < .001), schizophrenia (aHR, 0.73; 95% CI, 0.69-0.77; P < .001), and NAP (aHR, 0.85; 95% CI, 0.79-0.92; P < .001), and self-harm was reduced in BPD (aHR, 0.73; 95% CI, 0.62-0.84; P < .001) and schizophrenia (aHR, 0.64; 95% CI, 0.48-0.85; P < .001).This study provides additional evidence that exposure to HMG-CoA RIs, LTCC antagonists, and biguanides might lead to improved outcomes for individuals with SMI. Given the well-known adverse event profiles of these agents, they should be further investigated as repurposed agents for psychiatric symptoms.